| Literature DB >> 32218590 |
Fabiana Lauretti-Ferreira1,2, Paloma L D Silva2, Naiara M Alcântara2, Bruna F Silva2, Isabele Grabher2, Gisele O Souza3, Erika Nakajima4, Milena A Akamatsu1, Silvio A Vasconcellos3, Patricia A E Abreu2, Eneas Carvalho2, Elizabeth A L Martins4, Paulo L Ho1, Josefa B da Silva2.
Abstract
Pathogenic spirochetes from genus Leptospira are etiologic agents of leptospirosis. Cellular vaccines against Leptospira infection often elicit mainly response against the LPS antigen of the serovars present in the formulation. There is no suitable protein candidate capable of replacing whole-cell vaccines, thus requiring new approaches on vaccine development to improve leptospirosis prevention. Our goal was to develop a whole-cell vaccine sorovar-independent based on LPS removal and conservation of protein antigens exposure, to evaluate the protective capacity of monovalent or bivalent vaccines against homologous and heterologous virulent Leptospira in hamster. Leptospire were subjected to heat inactivation, or to LPS extraction with butanol and in some cases further inactivation with formaldehyde. Hamsters were immunized and challenged with homologous or heterologous virulent serovars, blood and organs were collected from the survivors for bacterial quantification, chemokine evaluation, and analysis of sera antibody reactivity and cross-reactivity by Western blot. Immunization with either heated or low LPS vaccines with serovar Copenhageni or Canicola resulted in 100% protection of the animals challenged with homologous virulent bacteria. Notably, different from the whole-cell vaccine, the low LPS vaccines produced with serovar Canicola provided only partial protection in heterologous challenge with the virulent Copenhageni serovar. Immunization with bivalent formulation results in 100% protection of immunized animals challenged with virulent serovar Canicola. All vaccines produced were able to eliminate bacteria from the kidney of challenged animals. All the vaccines raised antibodies capable to recognize antigens of serovars not present in the vaccine formulation. Transcripts of IFNγ, CXCL16, CCL5, CXCL10, CXCR6, and CCR5, increased in all immunized animals.Entities:
Year: 2020 PMID: 32218590 PMCID: PMC7100938 DOI: 10.1371/journal.pone.0230460
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Animal assays—experimental immunizations and challenge groups.
| Experiment | Vaccine | challenge | Survival/total (%) | |
|---|---|---|---|---|
| First dose | Second dose | |||
| A VacCop | PBS | PBS | Cop | 0/4 (0) |
| CopHeat | CopHeat | Cop (homologous) | 5/5 (100) | |
| CopBut | CopBut | Cop (homologous) | 5/5 (100) | |
| CopButForm | CopButForm | Cop (homologous) | 5/5 (100) | |
| B VacCan | PBS | PBS | Can | 1/5 (20) |
| CanHeat | CanHeat | Can (homologous) | 5/5 (100) | |
| CanBut | CanBut | Can (homologous) | 5/5 (100) | |
| CanButForm | CanButForm | Can (homologous) | 5/5 (100) | |
| C VacCop | PBS | PBS | Can | 0/4 (0) |
| CopHeat | CopHeat | Can (heterologous) | 0/4 (0) | |
| CopBut | CopBut | Can (heterologous) | 0/5 (0) | |
| CopButForm | CopButForm | Can (heterologous) | 0/5 (0) | |
| D VacCan | PBS | PBS | Cop | 0/5 (0) |
| CanHeat | CanHeat | Cop (heterologous) | 4/4 (100) | |
| CanBut | CanBut | Cop (heterologous) | 1/5 (20) | |
| CanButForm | CanButForm | Cop (heterologous) | 4/5 (80) | |
| E bivalent vaccines | PBS | PBS | Can | 0/4 (0) |
| CanCopHeat | CanCopHeat | Can | 4/4 (100) | |
| CanCopBut | CanCopBut | Can | 5/5 (100) | |
| CanCopButForm | CanCopButForm | Can | 5/5 (100) | |
| F Bi / mono valent vaccines | PBS | PBS | Can | 0/5 (0) |
| CanCopHeat | CopHeat | Can | 5/5 (100) | |
| CanCopBut | CopBut | Can | 5/5 (100) | |
| CanCopButForm | CopButForm | Can | 5/5 (100) | |
Cop-serovar Copenhageni; Can-serovar Canicola; VacCop-Copenhageni vaccine; VacCan-Canicola vaccine; Heat-treated vaccine; But-treated with Butanol; ButForm-treated with butanol and inactivated with formaldehyde.
Oligonucleotide sequences of specific genes of hamster and ribosomal gene of Leptospira.
| Gene | foward sequence | Tm °C | reverse sequence | Tm °C | amplicon length |
|---|---|---|---|---|---|
| cxcl16 | 62 | 62 | 99 | ||
| cxcr6 | 62 | 62 | 110 | ||
| ifn-γ | 63 | 63 | 89 | ||
| ccl5 | 62 | 62 | 102 | ||
| ccr5 | 62 | 62 | 100 | ||
| cxcl10 | 62 | 62 | 102 | ||
| gapdh | 62 | 62 | 110 | ||
| 16s | 62 | 62 | 97 |
Fig 1Protection of hamsters immunized and challenged with virulent Leptospira; a and b) represent data obtained from animals immunized with L. interrogans sv Copenhageni and L. interrogans sv Canicola, respectively, after immunization, these animals were challenged with the virulent serovar homologous to that of the vaccine preparations; c) data from animals immunized with sv Canicola, and challenged with sv Copenhageni (heterologous challenge); d and e) represent data obtained with bivalent vaccines (VacCanCop).
The first groups (d) received two doses of bivalent formulations, and (e) received the bivalent vaccine as first dose and second dose contained only the serovar Copenhageni (VacCop). Animals represented in graphic (d) and (e) were challenged with Canicola serovar after immunizations. Statistical analyzes were performed comparing survival curves by Log-rank (Mantel-Cox), followed by Gehan-Breslow-Wilcoxon test using GraphPad Prism software.
Fig 2Western blotting of antisera obtained from hamsters immunized and challenged with L. interrogans serovar Copenhageni or Canicola, analyzed against cell extracts from different Leptospira species and serovars.
Western blot images were obtained using sera collected from animals of different experimetal groups fifteen days after second dose immunization (left side) and thirty days after challenge (survivor animals) (right side). Immunization and challenge groups as indicated: a) VacCop challenge sv Copenhageni; b) VacCan challenge sv Canicola; c) VacCanCop challenge sv Canicola and d) VacCanCop first dose, VacCop second dose challenge Canicola. Different Leptospira cell extracts were prepared, separated by SDS-PAGE in 4–20% gradient gels (except Fig d HeatVac right, that was performed with 12% polyacrylamide). Pat—L. biflexa sv. Patoc; Cop—L. interrogans sv. Copenhageni; Ken—L. interrogans sv. Kennewich (Pomona LPF); Can—L. interrogans sv. Canicola (LO4); Har—L. interrogans sv. Hardjo (strain Hardjoprajitino); Ict—L. interrogans sv. Icterohaemorrhagiae (strain M20); Bat—L. interrogans sv. Bataviae (strain Van Tienen); L32—LipL32 recombinant protein; LMW—Low-Range and HMW—Full-Range (ECL Rainbow Molecular Weight Marker (GE Healthcare).
Fig 3Transcription levels of cytokines, chemokines and their receptors in kidney samples collected from hamsters immunized and challenged with L. interrogans sv Canicola.
Analysis of samples ware performed in triplicates, and two independents experiments. Cycle threshold (CT) values for specific genes were normalized to the CT values of chemokine genes with gapdh gene.